These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 8500877)

  • 1. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.
    Orr N; Robin G; Cohen D; Arnon R; Lowell GH
    Infect Immun; 1993 Jun; 61(6):2390-5. PubMed ID: 8500877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV; Turbyfill KR
    Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
    mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
    [No Abstract]   [Full Text] [Related]  

  • 5. Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines.
    Orr N; Arnon R; Rubin G; Cohen D; Bercovier H; Lowell GH
    Infect Immun; 1994 Nov; 62(11):5198-200. PubMed ID: 7927807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
    Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH; Ashkenazi S; Harlev E; Miron D; Ramon R; Farzam N; Lerner-Geva L; Levi Y; Chu C; Shiloach J; Robbins JB; Schneerson R;
    Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
    Riddle MS; Kaminski RW; Di Paolo C; Porter CK; Gutierrez RL; Clarkson KA; Weerts HE; Duplessis C; Castellano A; Alaimo C; Paolino K; Gormley R; Gambillara Fonck V
    Clin Vaccine Immunol; 2016 Dec; 23(12):908-917. PubMed ID: 27581434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection.
    Mallett CP; Hale TL; Kaminski RW; Larsen T; Orr N; Cohen D; Lowell GH
    Infect Immun; 1995 Jun; 63(6):2382-6. PubMed ID: 7768627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outer Membrane Vesicles Derived from
    Tian H; Li B; Xu T; Yu H; Chen J; Yu H; Li S; Zeng L; Huang X; Liu Q
    Appl Environ Microbiol; 2021 Sep; 87(19):e0096821. PubMed ID: 34319809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.
    Kaminski RW; Wu M; Turbyfill KR; Clarkson K; Tai B; Bourgeois AL; Van De Verg LL; Walker RI; Oaks EV
    Clin Vaccine Immunol; 2014 Mar; 21(3):366-82. PubMed ID: 24403527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S; Passwell JH; Harlev E; Miron D; Dagan R; Farzan N; Ramon R; Majadly F; Bryla DA; Karpas AB; Robbins JB; Schneerson R
    J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.
    Fries LF; Montemarano AD; Mallett CP; Taylor DN; Hale TL; Lowell GH
    Infect Immun; 2001 Jul; 69(7):4545-53. PubMed ID: 11401998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis.
    Mitra S; Chakrabarti MK; Koley H
    Vaccine; 2013 Jun; 31(31):3163-73. PubMed ID: 23684822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
    Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979
    [No Abstract]   [Full Text] [Related]  

  • 16. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study.
    Chisenga CC; Bosomprah S; Simuyandi M; Mwila-Kazimbaya K; Chilyabanyama ON; Laban NM; Bialik A; Asato V; Meron-Sudai S; Frankel G; Cohen D; Chilengi R
    PLoS One; 2021; 16(5):e0252222. PubMed ID: 34043697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization and quantitative analysis of serum IgG class and subclass response to Shigella sonnei and Shigella flexneri 2a lipopolysaccharide following natural Shigella infection.
    Robin G; Cohen D; Orr N; Markus I; Slepon R; Ashkenazi S; Keisari Y
    J Infect Dis; 1997 May; 175(5):1128-33. PubMed ID: 9129076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
    Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA
    J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a.
    Dharmasena MN; Hanisch BW; Wai TT; Kopecko DJ
    Int J Med Microbiol; 2013 Apr; 303(3):105-13. PubMed ID: 23474241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.
    Taylor DN; Trofa AC; Sadoff J; Chu C; Bryla D; Shiloach J; Cohen D; Ashkenazi S; Lerman Y; Egan W
    Infect Immun; 1993 Sep; 61(9):3678-87. PubMed ID: 8359890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.